FDA Approves Lemborexant for Insomnia in Adults
The small molecule orexin receptor antagonist will be made available for the US market in 2 different doses, in 2020.
The small molecule orexin receptor antagonist will be made available for the US market in 2 different doses, in 2020.
Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.
The FDA approved an expanded label for avacincaptad pegol, removing limitations on the duration of dosing beyond 12 months.
This interview highlights the significance of Bruckner’s recent phase 3 data on birch triterpenes as a potential treatment for dystrophic and junctional EB, as well…
Evaluate efficacy and show safety results of Risankizumab vs Ustekinumab for the treatment of moderate-to-severe Crohn’s Disease. Explore the study design and outcomes of Risankizumab’s…
A study found higher daily temperatures increased anaphylaxis risk, except for cases related to medical procedures, highlighting heat’s role in allergic reactions.
In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.
This approval by the FDA of Evolus’s 2 new hyaluronic acid gels provides an additional set of options for dermatologists in the aesthetic products market.
A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.
In these new findings, investigators highlight phase 1 research into ritlecitinib for patients aged 6 to 12 years with alopecia areata.
Patients with adenomas had a greater risk of colorectal cancer, and advanced adenomas were linked to a greater risk of cancer-related and all-cause mortality.